

Docket No. 60425 PCT

APPLICANT:

Neurogen Corporation

INVENTORS:

R. Bakthavatchalam et al.

INT. APPLN. NO.:

PCT/US03/39607

FILED:

12 December 2003

FOR:

ACID-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Facsimile No.: 011 41 22 740 14 35

SIR:

REQUEST TO CORRECT INVENTOR'S ADDRESS UNDER RULE 92BIS

Applicants have noticed that the international publication incorrectly states the zip code of inventor Rajagopal Bakthavatchalam as "06437" and it should read --06443--. In addition, inventor Timothy Caldwell's address should read --244 South Union Street, Guilford, CT 06437--.

Applicants request that the zip code of Rajagopal Bakthavatchalam and the address of inventor Timothy Caldwell be correctly listed in the international publication.

Accordingly, enclosed please find:

A Marked up copy of the first page of International Patent
 Publication PCT/2004/055004 A1, indicating the correct zip code of
 Rajagopal Bakthavatchalam and the address of inventor Timothy
 Caldwell.

Please contact the undersigned attorney if any additional information is needed.

Respectfully submitted,

John By Alexander, Ph.D. (Reg. 48,399)

Edwards & Angell, LLP

PO Box 55874 Boston MA 02205

(617) 439-4444

(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 1 July 2004 (01.07.2004)

(10) International Publication Number WO 2004/055004 A1

(51) International Patent Classification7: 471/04, C07F 9/09, 9/38

C07D 401/04,

(US). ZHENG, Xiaozhang [CN/US]; 10 Roby Court, Branford, CT 06405 (US).

(21) International Application Number:

PCT/US2003/039607

(74) Agents: ALEXANDER, John, B., Ph., D. et al.; Edwards & Angell, LLP, P.O. Box 9169, Boston, MA 02209 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,

(22) International Filing Date:

12 December 2003 (12.12.2003)

(25) Filing Language:

English

(26) Publication Language:

English

60/433,139

(30) Priority Data:

13 December 2002 (13.12.2002)

AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): NEURO-GEN CORPORATION [US/US]; 35 Northeast Industrial Road, Branford, CT 06405 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BAKTHA-VATCHALAM, Rajagopal [US/US]; 67 Hickory Lane, Madison, CT (06437) (US). BLUM, Charles, A. [US/US]; 785 W. Pond Meadow Rd., Westbrook, CT 06498 (US). BRIELMANN, Harry [US/US]; 14 Elm Street, Guilford, CT 06437 (US). CALDWELL, Timothy, M. [US/US]; 35 Indian Neck Avenue, Branford, CT 06405 (US). DE LOMBAERT, Stephane [BE/US]; 37 Concord Drive, Madison, CT 06443 (US). HODGETTS, Kevin, J. [GB/US]; 224 Reservoir Road, Killingworth, CT 06419

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

06443

244 South Union Street Guilford, CT 06437

VO 2004/055004 A1 CARBOXYLIC ACID, PHOSPHATE OR PHOSPHONATE SUBSTITUTED QUINAZOLIN-4-YLAMINE (54) Title: ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS

(57) Abstract: Acid-substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

**************************************		********* NSACTION	****** REPORT	****	***************************************	P. 01
DATE START RECI	IVER	TX TIME	PAGES	- TYPE	JC17 Rec'd FCT/PTO NOTE	THU 302 ; 39 PM 20 \$ 5
JUN-02 02:38 PM 0114	1227401435	1′ 48″	3	SEND	OK	089 *

TOTAL:

Edwards & Angell

101 Federal Street Boston, MA 02110 617.439.4444 fax 617.439.4170 www.EdwardsAngell.com

Date: June 2, 2005

Pages (including cover): 3

1M 48S PAGES:

Sender:

Name John B. Alexander

Fax 617.439.4170

JAlexander@EdwardsAngell.com

Phone 617.517.5555

To:

Email

Name Company

Fax

Phone

The International Bureau of WIPO

011 41 22 740 14 35

If you experience problems receiving this fax, please call Michelle P. Chicos at 617.517.5551.

Message:

Enclosed please find a Request to Correct Inventor's Address Under Rule 92^{bis} in connection with U.S. Serial No. PCT/US2003/039607.



101 Federal Street Boston, MA 02110 617.439.4444 fax 617.439.4170 www.EdwardsAngell.com

Date: June 2, 2005 Pages (including cover): 3

Sender:

Name John B. Alexander

Fax 617.439.4170

Email JAlexander@EdwardsAngell.com

Phone

617.517.5555

To:

Name Company

Fax

Phone

The International Bureau of WIPO

011 41 22 740 14 35

If you experience problems receiving this fax, please call Michelle P. Chicos at 617.517.5551.

Message:

Enclosed please find a Request to Correct Inventor's Address Under Rule 92^{bis} in connection with U.S. Serial No. PCT/US2003/039607.

Please do not hesitate to contact me if you have any questions, or if I can be of any further assistance at this time.

Best Regards,

John B. Alexander, Ph.D.

JBA:mpc

Fax

Confidentiality Note: The documents accompanying this facsimile contain information from the law firm of Edwards & Angell LLP, which may be confidential and/or privileged. The information is intended only for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying distribution or the taking of any action in reliance on the contents of this facsimile is strictly prohibited, and that the documents should be returned to this firm immediately. If you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the return of the original documents to us at no cost to you.